A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy
Recruiting · NCT07654972 · Interventional (participants receive a specific treatment)
View the official record on ClinicalTrials.gov →Interventions studied
LY4174794Placebo
What this trial is about
The main purpose of this study is to understand how safe and well-tolerated LY4174794 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4174794 gets into the bloodstream and how long it takes the body to eliminate it. Participation in this study will last about 30 to 39 weeks (7 to 10 months).
Who can take part
Age range
18 Years to 65 Years
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Phase 1
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Are overtly healthy with no comorbidities related to body mass index (BMI), such as type 2 diabetes mellitus or unstable cardiovascular disease
- Are overweight with a BMI of ≥27 kilogram per meter square (kg/m²), or have obesity with a BMI of ≥30 kg/ m²
- Have had a self-reported stable weight for 3 months prior to screening
Exclusion criteria
- Have a history or presence of cardiovascular, respiratory, hepatic, renal, GI, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study intervention, or of interfering with the interpretation of data
- Is an individual of childbearing potential (IOCBP)
Where it is running
3 locations listed across 2 US states.
- ICON Early Phase Services, LLC - San Antonio, Texas, United States
- ICON Early Phase Services, LLC - Salt Lake City, Utah, United States
- Lilly Centre for Clinical Pharmacology - Singapore, Singapore